Production (Stage)
ArriVent BioPharma, Inc.
AVBP
$20.40
-$0.23-1.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.48M | 3.54M | 4.14M | 3.92M | 3.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.77M | 23.71M | 24.23M | 25.70M | 20.67M |
| Operating Income | -26.77M | -23.71M | -24.23M | -25.70M | -20.67M |
| Income Before Tax | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M |
| EBIT | -26.77M | -23.71M | -24.23M | -25.70M | -20.67M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.90 | -0.61 | -0.61 | -0.65 | -0.70 |
| Normalized Basic EPS | -0.45 | -0.38 | -0.38 | -0.41 | -0.43 |
| EPS Diluted | -1.90 | -0.61 | -0.61 | -0.65 | -0.70 |
| Normalized Diluted EPS | -0.45 | -0.38 | -0.38 | -0.41 | -0.43 |
| Average Basic Shares Outstanding | 33.90M | 33.72M | 33.58M | 33.50M | 25.05M |
| Average Diluted Shares Outstanding | 33.90M | 33.72M | 33.58M | 33.50M | 25.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |